Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Surrozen Inc's Business Segments
Surrozen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Collaboration and license revenue
Total Revenue
$ 5
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Collaboration and license revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and license revenue | $ 10 | - |
Revenue by Product & Service Category - FY
- Collaboration and license revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and license revenue | $ 5 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Collaboration and license revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and license revenue | $ 10 | - |
Description of Surrozen Inc
Surrozen Inc. is a biotechnology company that specializes in discovering and developing regenerative medicines to treat various diseases and conditions. The company's primary focus lies in harnessing the power of the Wnt signaling pathway, which is crucial for tissue regeneration and repair.
Surrozen Inc. was founded in 2016 by four prominent scientists: K. Christopher Garcia, Roel Nusse, Calvin Kuo, and Claudia Janda. Each of them brought their expertise in molecular biology, stem cell biology, and tissue regeneration to establish a robust foundation for the company.
The core mission of Surrozen is to develop novel therapeutics that can support tissue regeneration in patients suffering from various disorders, including musculoskeletal diseases, gastrointestinal disorders, and neurodegenerative conditions. By targeting the Wnt signaling pathway, Surrozen aims to promote the repair and regeneration of damaged tissues.
The company has created a unique technology platform called Surround, which enables them to design and develop monoclonal antibodies that precisely target and modulate the Wnt pathway. These antibodies can either activate or inhibit specific Wnt signaling components, allowing for precise control over tissue regeneration.
Surrozen's research and development efforts are supported by a multidisciplinary team of scientists, including biologists, chemists, pharmacologists, and clinicians. This diverse talent pool allows for an integrated and comprehensive approach to drug discovery and development.
One area where Surrozen has made significant progress is in the development of regenerative therapies for diseases of the liver. By activating specific Wnt signaling components, the company has shown promising results in preclinical models, where liver tissue regeneration was observed. This research holds the potential to revolutionize the treatment of liver diseases, such as cirrhosis and fatty liver disease.
In addition to liver diseases, Surrozen is also actively exploring the therapeutic potential of their Wnt-modulating antibodies in other areas, such as osteoarthritis, inflammatory bowel disease, and neurodegenerative disorders like Parkinson's disease and Alzheimer's disease.
The company has successfully raised substantial financing to support its research and development activities. Surrozen has secured funding from various renowned venture capital firms and investors, including The Column Group, SkyViews Life Science, and Hartford HealthCare. These investments demonstrate the confidence in Surrozen's technology platform and its potential to transform the field of regenerative medicine.
Overall, Surrozen Inc. is a pioneering biotech company at the forefront of regenerative medicine. Through its innovative approach to modulating the Wnt signaling pathway, Surrozen aims to develop transformative therapies to restore and repair damaged tissues in a wide range of diseases and conditions.
Surrozen Inc. was founded in 2016 by four prominent scientists: K. Christopher Garcia, Roel Nusse, Calvin Kuo, and Claudia Janda. Each of them brought their expertise in molecular biology, stem cell biology, and tissue regeneration to establish a robust foundation for the company.
The core mission of Surrozen is to develop novel therapeutics that can support tissue regeneration in patients suffering from various disorders, including musculoskeletal diseases, gastrointestinal disorders, and neurodegenerative conditions. By targeting the Wnt signaling pathway, Surrozen aims to promote the repair and regeneration of damaged tissues.
The company has created a unique technology platform called Surround, which enables them to design and develop monoclonal antibodies that precisely target and modulate the Wnt pathway. These antibodies can either activate or inhibit specific Wnt signaling components, allowing for precise control over tissue regeneration.
Surrozen's research and development efforts are supported by a multidisciplinary team of scientists, including biologists, chemists, pharmacologists, and clinicians. This diverse talent pool allows for an integrated and comprehensive approach to drug discovery and development.
One area where Surrozen has made significant progress is in the development of regenerative therapies for diseases of the liver. By activating specific Wnt signaling components, the company has shown promising results in preclinical models, where liver tissue regeneration was observed. This research holds the potential to revolutionize the treatment of liver diseases, such as cirrhosis and fatty liver disease.
In addition to liver diseases, Surrozen is also actively exploring the therapeutic potential of their Wnt-modulating antibodies in other areas, such as osteoarthritis, inflammatory bowel disease, and neurodegenerative disorders like Parkinson's disease and Alzheimer's disease.
The company has successfully raised substantial financing to support its research and development activities. Surrozen has secured funding from various renowned venture capital firms and investors, including The Column Group, SkyViews Life Science, and Hartford HealthCare. These investments demonstrate the confidence in Surrozen's technology platform and its potential to transform the field of regenerative medicine.
Overall, Surrozen Inc. is a pioneering biotech company at the forefront of regenerative medicine. Through its innovative approach to modulating the Wnt signaling pathway, Surrozen aims to develop transformative therapies to restore and repair damaged tissues in a wide range of diseases and conditions.
Surrozen Inc: Comprehensive Overview of Segments, Products, and Services
Surrozen Inc. is a pioneering biotechnology company dedicated to advancing the field of regenerative medicine. Through innovative therapies that focus on tissue regeneration and organ engineering, the company aims to revolutionize treatment options for a variety of medical conditions. Below is an extensive overview of Surrozens operational segments, product offerings, and services.
1. Segments
a. Tissue Regeneration
Surrozens primary focus within tissue regeneration encompasses the enhancement and repair of various tissues, including:
- Muscle Tissue: Development of therapies to regenerate damaged muscle tissues, particularly following injuries or degenerative diseases. These may involve the use of myoblasts or other muscle precursor cells.
- Bone Tissue: Efforts in this segment aim to facilitate bone healing in conditions such as osteoporosis and fractures. Surrozen investigates the application of osteogenic growth factors to stimulate bone formation.
- Nerve Tissue: Surrozen is dedicated to repairing nerve damage through innovative approaches, including neural stem cell therapies and the application of neurotrophic factors to enhance nerve regeneration.
- Skin Tissue: The company is also involved in the regeneration and repair of skin, focusing on wound healing and scar reduction through cell-based technologies or growth factor applications.
b. Organ Engineering
Surrozen is at the forefront of organ engineering initiatives, working on various vital organs using advanced methodologies, such as:
- Heart Engineering: Surrozen seeks to develop therapies aimed at regenerating heart tissue, particularly for conditions such as myocardial infarction, through cardiac stem cells and growth factors.
- Liver Engineering: Efforts in this area include the development of liver organoids that mimic organ function for disease modeling and potential transplantation applications.
- Kidney Engineering: The company explores the use of nephron progenitor cells and bioengineered kidney constructs that hold the potential to address chronic kidney diseases.
- Lung Engineering: Initiatives to regenerate lung tissue are vital for patients suffering from diseases such as COPD or pulmonary fibrosis, with a focus on epithelial cells and other lung-specific progenitor cells.
Products
a. Stem Cell Therapies
Surrozen offers a portfolio of stem cell-based products designed to utilize the inherent regenerative capabilities of specific cell types. These therapies target conditions ranging from injuries to chronic diseases, with a focus on:
- Cell Therapies: Utilization of both autologous (from the patient) and allogeneic (donor-derived) stem cells to promote tissue repair.
- Induced Pluripotent Stem Cells (iPSCs): Development and application of iPSCs for creating patient-specific therapies that can differentiate into the required tissue type.
b. Growth Factors
The company specializes in the production and delivery of growth factors that play a crucial role in tissue and organ regeneration. These include:
- Protein-based Growth Factors: Development of recombinant proteins that stimulate cellular processes vital for healing and regeneration.
- Gene Therapy Approaches: Utilizing viral vectors or plasmids to deliver growth factor genes directly to target tissues, enhancing regenerative capabilities.
c. Biomaterials
Surrozen is engaged in the design and development of novel biomaterials that facilitate cell growth, differentiation, and integration within engineered tissues. These include:
- Scaffolding Materials: Biodegradable and biocompatible scaffolds that support cellular infiltration and tissue maturation.
- Hydrogels and 3D Constructs: Advanced hydrogels designed to replicate the extracellular matrix, providing a conducive environment for cell attachment and function.
Services
a. Preclinical Studies
Surrozen conducts robust preclinical studies aimed at assessing the safety, efficacy, and pharmacokinetics of its regenerative medicine products. These studies inform product development and regulatory strategies.
b. Regenerative Medicine Consultancy
The company offers its expertise in regenerative medicine through consultancy services directed at academic institutions, biotech firms, and healthcare organizations. This includes:
- Product Development Guidance: Assistance in navigating the complexities of developing regenerative therapies from concept through to commercialization.
- Regulatory Strategy Consultation: Expert advice on compliance with regulatory standards and pathways for emerging regenerative medicine products.
c. Collaborative Research
Surrozen actively seeks partnerships with academic and industrial entities to conduct collaborative research projects. These partnerships aim to leverage combined resources and expertise to:
- Accelerate Innovation: Joint efforts in technology development can lead to novel therapeutic approaches and applications.
- Enhance Knowledge Share: Collaborative projects can foster shared learning and speed up the translation of scientific research into viable clinical solutions.
Conclusion
Surrozen Inc. is a leader in the biotechnology landscape, making significant contributions to the fields of tissue regeneration and organ engineering. With a diverse portfolio that includes stem cell therapies, growth factors, and advanced biomaterials, Surrozen not only addresses pressing medical needs but also offers comprehensive services that underpin the development of innovative regenerative therapies. Through their commitment to scientific excellence and collaborative research, Surrozen continues to push the boundaries of whats possible in regenerative medicine.
Surrozen Inc. is a pioneering biotechnology company dedicated to advancing the field of regenerative medicine. Through innovative therapies that focus on tissue regeneration and organ engineering, the company aims to revolutionize treatment options for a variety of medical conditions. Below is an extensive overview of Surrozens operational segments, product offerings, and services.
1. Segments
a. Tissue Regeneration
Surrozens primary focus within tissue regeneration encompasses the enhancement and repair of various tissues, including:
- Muscle Tissue: Development of therapies to regenerate damaged muscle tissues, particularly following injuries or degenerative diseases. These may involve the use of myoblasts or other muscle precursor cells.
- Bone Tissue: Efforts in this segment aim to facilitate bone healing in conditions such as osteoporosis and fractures. Surrozen investigates the application of osteogenic growth factors to stimulate bone formation.
- Nerve Tissue: Surrozen is dedicated to repairing nerve damage through innovative approaches, including neural stem cell therapies and the application of neurotrophic factors to enhance nerve regeneration.
- Skin Tissue: The company is also involved in the regeneration and repair of skin, focusing on wound healing and scar reduction through cell-based technologies or growth factor applications.
b. Organ Engineering
Surrozen is at the forefront of organ engineering initiatives, working on various vital organs using advanced methodologies, such as:
- Heart Engineering: Surrozen seeks to develop therapies aimed at regenerating heart tissue, particularly for conditions such as myocardial infarction, through cardiac stem cells and growth factors.
- Liver Engineering: Efforts in this area include the development of liver organoids that mimic organ function for disease modeling and potential transplantation applications.
- Kidney Engineering: The company explores the use of nephron progenitor cells and bioengineered kidney constructs that hold the potential to address chronic kidney diseases.
- Lung Engineering: Initiatives to regenerate lung tissue are vital for patients suffering from diseases such as COPD or pulmonary fibrosis, with a focus on epithelial cells and other lung-specific progenitor cells.
Products
a. Stem Cell Therapies
Surrozen offers a portfolio of stem cell-based products designed to utilize the inherent regenerative capabilities of specific cell types. These therapies target conditions ranging from injuries to chronic diseases, with a focus on:
- Cell Therapies: Utilization of both autologous (from the patient) and allogeneic (donor-derived) stem cells to promote tissue repair.
- Induced Pluripotent Stem Cells (iPSCs): Development and application of iPSCs for creating patient-specific therapies that can differentiate into the required tissue type.
b. Growth Factors
The company specializes in the production and delivery of growth factors that play a crucial role in tissue and organ regeneration. These include:
- Protein-based Growth Factors: Development of recombinant proteins that stimulate cellular processes vital for healing and regeneration.
- Gene Therapy Approaches: Utilizing viral vectors or plasmids to deliver growth factor genes directly to target tissues, enhancing regenerative capabilities.
c. Biomaterials
Surrozen is engaged in the design and development of novel biomaterials that facilitate cell growth, differentiation, and integration within engineered tissues. These include:
- Scaffolding Materials: Biodegradable and biocompatible scaffolds that support cellular infiltration and tissue maturation.
- Hydrogels and 3D Constructs: Advanced hydrogels designed to replicate the extracellular matrix, providing a conducive environment for cell attachment and function.
Services
a. Preclinical Studies
Surrozen conducts robust preclinical studies aimed at assessing the safety, efficacy, and pharmacokinetics of its regenerative medicine products. These studies inform product development and regulatory strategies.
b. Regenerative Medicine Consultancy
The company offers its expertise in regenerative medicine through consultancy services directed at academic institutions, biotech firms, and healthcare organizations. This includes:
- Product Development Guidance: Assistance in navigating the complexities of developing regenerative therapies from concept through to commercialization.
- Regulatory Strategy Consultation: Expert advice on compliance with regulatory standards and pathways for emerging regenerative medicine products.
c. Collaborative Research
Surrozen actively seeks partnerships with academic and industrial entities to conduct collaborative research projects. These partnerships aim to leverage combined resources and expertise to:
- Accelerate Innovation: Joint efforts in technology development can lead to novel therapeutic approaches and applications.
- Enhance Knowledge Share: Collaborative projects can foster shared learning and speed up the translation of scientific research into viable clinical solutions.
Conclusion
Surrozen Inc. is a leader in the biotechnology landscape, making significant contributions to the fields of tissue regeneration and organ engineering. With a diverse portfolio that includes stem cell therapies, growth factors, and advanced biomaterials, Surrozen not only addresses pressing medical needs but also offers comprehensive services that underpin the development of innovative regenerative therapies. Through their commitment to scientific excellence and collaborative research, Surrozen continues to push the boundaries of whats possible in regenerative medicine.